OABI · Omniab, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.43M | - | $2.24M | $3.90M | $4.15M | - | $4.17M | $7.61M | $3.80M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $9.64M | - | $10.38M | $10.86M | $12.60M | - | $13.32M | $13.94M | $14.55M | - |
| SG&A | $6.62M | - | $6.78M | $7.68M | $7.92M | - | $7.08M | $7.96M | $8.34M | - |
| Total Operating Expenses | $22.26M | - | $20.38M | $20.12M | $23.00M | - | $23.94M | $23.92M | $26.35M | - |
| D&A | $606.0K | - | $900.0K | $800.0K | $4.74M | - | $1.00M | $1.10M | $4.95M | - |
| Operating Income | ($7.83M) | - | ($18.14M) | ($16.22M) | ($18.84M) | - | ($19.76M) | ($16.30M) | ($22.55M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $442.0K | - | ($1.16M) | $119.0K | ($106.0K) | - | ($2.71M) | ($1.90M) | ($2.62M) | - |
| Net Income | ($7.71M) | - | ($16.52M) | ($15.88M) | ($18.20M) | - | ($16.37M) | ($13.63M) | ($18.96M) | - |
| EPS - Basic | ($0.06) | - | ($0.14) | ($0.15) | ($0.17) | - | ($0.16) | ($0.13) | ($0.19) | - |
| EPS - Diluted | ($0.06) | - | ($0.14) | ($0.15) | ($0.17) | - | ($0.16) | ($0.13) | ($0.19) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.05M | $25.52M | $28.54M | $18.28M | $10.89M | $27.60M | $27.24M | $20.79M | $19.06M | $16.36M |
| Accounts Receivable | $12.64M | $7.39M | $3.10M | $2.71M | $6.48M | $5.27M | $3.50M | $6.88M | $4.04M | $3.84M |
| Inventory | $920.0K | $823.0K | $443.0K | $48.0K | - | - | - | - | - | - |
| Accounts Payable | $1.65M | $1.88M | $1.91M | $1.98M | $1.93M | $2.30M | $2.19M | $2.81M | $3.56M | $4.41M |
| Current Assets | $65.13M | $65.34M | $66.35M | $47.62M | $53.58M | $68.14M | $66.61M | $67.30M | $76.72M | $94.90M |
| Total Assets | $293.65M | $300.91M | $309.69M | $295.67M | $306.18M | $325.56M | $331.55M | $337.26M | $352.56M | $375.23M |
| Current Liabilities | $13.57M | $16.25M | $13.28M | $12.64M | $11.41M | $15.09M | $14.40M | $14.15M | $17.52M | $23.12M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $31.00M | $33.89M | $32.25M | $33.61M | $32.67M | $37.94M | $39.83M | $43.08M | $51.16M | $60.64M |
| Stockholders' Equity | $262.65M | $267.03M | $277.44M | $262.06M | $273.52M | $287.62M | $291.73M | $294.18M | $301.39M | $314.58M |
| Retained Earnings | ($173.89M) | ($166.18M) | ($152.00M) | ($135.47M) | ($119.60M) | ($101.40M) | ($88.33M) | ($71.96M) | ($58.33M) | ($39.37M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.91M) | - | - | - | ($15.87M) | - | - | - | ($17.03M) | - |
| Investing Cash Flow | $8.44M | - | - | - | ($878.0K) | - | - | - | $19.94M | - |
| Financing Cash Flow | $0 | - | - | - | $44.0K | - | - | - | ($203.0K) | - |
| CapEx | $167.0K | - | - | - | $209.0K | - | - | - | $926.0K | - |
| Free Cash Flow | ($5.08M) | - | - | - | ($16.08M) | - | - | - | ($17.96M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -54.3% | - | -810.2% | -416.2% | -453.6% | - | -473.7% | -214.1% | -593.3% | - |
| EBITDA margin | -50.1% | - | -770.0% | -395.7% | -339.5% | - | -449.8% | -199.7% | -463.1% | - |
| Net margin | -53.4% | - | -738.1% | -407.4% | -438.1% | - | -392.4% | -179.0% | -498.8% | - |
| Free cash flow margin | -35.2% | - | - | - | -387.1% | - | - | - | -472.5% | - |
| FCF / Net income | 0.66 | - | - | - | 0.88 | - | - | - | 0.95 | - |
| R&D / Revenue | 66.8% | - | 463.6% | 278.8% | 303.4% | - | 319.2% | 183.0% | 382.8% | - |
| SG&A / Revenue | 45.9% | - | 302.7% | 197.2% | 190.5% | - | 169.7% | 104.6% | 219.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -2.6% | - | -5.3% | -5.4% | -5.9% | - | -4.9% | -4.0% | -5.4% | - |
| Return on equity | -2.9% | - | -6.0% | -6.1% | -6.7% | - | -5.6% | -4.6% | -6.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.80 | 4.02 | 5.00 | 3.77 | 4.70 | 4.52 | 4.62 | 4.75 | 4.38 | 4.11 |
| Quick ratio | 4.73 | 3.97 | 4.96 | 3.76 | 4.70 | 4.52 | 4.62 | 4.75 | 4.38 | 4.11 |
| Cash ratio | 2.14 | 1.57 | 2.15 | 1.45 | 0.95 | 1.83 | 1.89 | 1.47 | 1.09 | 0.71 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.12 | 1.13 | 1.12 | 1.13 | 1.12 | 1.13 | 1.14 | 1.15 | 1.17 | 1.19 |
| Liabilities / Assets | 0.11 | 0.11 | 0.10 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.15 | 0.16 |
| Efficiency | ||||||||||
| Asset turnover | 0.05 | - | 0.01 | 0.01 | 0.01 | - | 0.01 | 0.02 | 0.01 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 320d | - | 505d | 253d | 569d | - | 306d | 330d | 388d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.8x | - | 0.7x | 0.7x | 0.9x | - | 1.5x | 1.3x | 1.8x | - |
| P / S | 14.0x | - | 82.0x | 47.4x | 61.0x | - | 103.8x | 50.0x | 143.7x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 247.3% | - | -46.3% | -48.8% | 9.3% | - | -39.6% | 5.8% | -77.5% | - |
| Revenue CAGR (3y) | -5.2% | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 58.5% | - | 8.2% | 0.5% | 16.4% | - | 2.7% | 16.1% | -166.8% | - |
| Net income growth (YoY) | 57.7% | - | -0.9% | -16.5% | 4.0% | - | -4.0% | 7.4% | -210.8% | - |
| EPS growth (YoY) | 64.7% | - | 12.5% | -15.4% | 10.5% | - | 0.0% | -8.3% | -137.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 68.4% | - | - | - | 10.5% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -4.0% | -7.2% | -4.9% | -10.9% | -9.2% | -8.6% | -10.1% | -11.9% | -11.6% | -7.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$18.67M totalReportable Segment$18.67M · 100.0%
Product / service
$18.67M totalLicense And Milestone Revenue$9.77M · 52.3%
Service$7.26M · 38.9%
Royalty$878.0K · 4.7%
XPloration Revenue$754.0K · 4.0%
Peer comparison
Same SIC group: Services-Commercial Physical & Biological Research
Comparing OmniAb against the 5 most active filers in the same SIC group.